# Altimmune, Inc.: overview ALT · Nasdaq · CIK 1326190 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/alt.md) · [Financials](/companies/alt/financials.md) · [Filings](/companies/alt/filings.md) · [Insiders](/companies/alt/insiders.md) Latest reported revenue: [$26.0k](/filings/0001326190-26-000018.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 6, 2026 (XBRL us-gaap:Revenues, accession 0001326190-26-000018). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001326190-25-000064.md) | [0.0 d](/filings/0001326190-26-000018.md) | [0.0](/filings/0001326190-26-000040.md) | [0.0](/filings/0001326190-26-000052.md) | [0.0](/filings/0001326190-25-000064.md) | [0.0 d](/filings/0001326190-26-000018.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(495340.0%)](/filings/0001326190-25-000064.md) | [(497320.0%) d](/filings/0001326190-26-000018.md) | [(436300.0%)](/filings/0001326190-26-000040.md) | [(458440.0%)](/filings/0001326190-26-000052.md) | [(417180.0%)](/filings/0001326190-25-000064.md) | [(111126.9%) d](/filings/0001326190-26-000018.md) | not reported | not reported | | Net margin | % | [(456900.0%)](/filings/0001326190-25-000064.md) | [(463600.0%) d](/filings/0001326190-26-000018.md) | [(391500.0%)](/filings/0001326190-26-000052.md) | [(442920.0%)](/filings/0001326190-26-000052.md) | [(380280.0%)](/filings/0001326190-25-000064.md) | [(105223.1%) d](/filings/0001326190-26-000018.md) | not reported | not reported | | Diluted EPS | $ per share | [(0.32)](/filings/0001326190-25-000064.md) | not reported | [(0.26)](/filings/0001326190-26-000040.md) | [(0.27)](/filings/0001326190-26-000052.md) | [(0.21)](/filings/0001326190-25-000064.md) | not reported | [(0.18)](/filings/0001326190-26-000040.md) | [(0.12)](/filings/0001326190-26-000052.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | [(11.9) d](/filings/0001326190-25-000064.md) | [(19.4) d](/filings/0001326190-26-000018.md) | [(21.0)](/filings/0001326190-26-000040.md) | [(24.3) d](/filings/0001326190-26-000052.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.4](/filings/0001558370-22-003659.md) | [(0.1)](/filings/0001326190-24-000010.md) | [0.4](/filings/0001326190-25-000015.md) | [0.0](/filings/0001326190-26-000018.md) | [0.0](/filings/0001326190-26-000018.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(2197.4%)](/filings/0001326190-23-000008.md) | [129029.4%](/filings/0001326190-24-000010.md) | [(22518.5%)](/filings/0001326190-25-000015.md) | [(515860.0%)](/filings/0001326190-26-000018.md) | [(230461.0%)](/filings/0001326190-26-000018.md) | | Net margin | % | [(2201.4%)](/filings/0001326190-23-000008.md) | [124577.9%](/filings/0001326190-24-000010.md) | [(20762.2%)](/filings/0001326190-25-000015.md) | [(475295.0%)](/filings/0001326190-26-000018.md) | [(214861.0%)](/filings/0001326190-26-000018.md) | | Diluted EPS | $ per share | [(2.35)](/filings/0001326190-23-000008.md) | [(1.81)](/filings/0001326190-24-000010.md) | [(1.66)](/filings/0001326190-25-000015.md) | [(1.34)](/filings/0001326190-26-000018.md) | [(1.00)](/filings/0001326190-26-000018.md) | | Free cash flow | $m | [(90.4)](/filings/0001326190-23-000008.md) | [(62.7)](/filings/0001326190-24-000010.md) | [(75.9)](/filings/0001326190-25-000015.md) | not reported | [(67.5)](/filings/0001326190-26-000018.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/alt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $62.0m | 20,385,284 | | Added +7,590,007 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $58.5m | 19,250,000 | | New +19,250,000 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $36.8m | 12,098,540 | | Added +4,952,990 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $30.4m | 10,000,000 | | New +10,000,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $24.9m | 8,177,752 | | Added +2,519,703 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $22.3m | 7,330,265 | | Added +1,948,263 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $20.8m | 6,841,055 | | Added +2,823,154 | | [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $20.4m | 6,700,000 | | New +6,700,000 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $19.8m | 6,500,000 | | New +6,500,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $15.2m | 5,011,314 | | Added +1,904,218 | ## Recent filings [All 1,180 filings](/companies/alt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 08:16 ET | [8-K](/filings/0001104659-26-118991.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-118991 | | 2026-09-29 | 07:03 ET | [8-K](/filings/0001326190-26-000056.md) | 5.02 Departure or appointment of officers or directors | 0001326190-26-000056 | | 2026-08-12 | 16:04 ET | [10-Q](/filings/0001326190-26-000052.md) | Quarterly report, period 2026-06-30 | 0001326190-26-000052 | | 2026-08-12 | 07:33 ET | [8-K](/filings/0001326190-26-000049.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001326190-26-000049 | | 2026-07-28 | 07:04 ET | [8-K](/filings/0001326190-26-000044.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001326190-26-000044 | | 2026-06-16 | 16:05 ET | [8-K](/filings/0001104659-26-074575.md) | 8.01 Other events | 0001104659-26-074575 | | 2026-05-13 | 16:13 ET | [10-Q](/filings/0001326190-26-000040.md) | Quarterly report, period 2026-03-31 | 0001326190-26-000040 | | 2026-05-13 | 07:34 ET | [8-K](/filings/0001326190-26-000037.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001326190-26-000037 | | 2026-04-24 | 16:05 ET | [8-K](/filings/0001104659-26-048552.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-048552 | | 2026-04-16 | 17:07 ET | [8-K](/filings/0001326190-26-000027.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001326190-26-000027 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001326190-26-000018.md), filed Mar 6, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1326190 - Tickers: ALT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 07:04 ET. No prices; not investment advice.